OmniAb (OABI) Investor Update summary

Launch of OmniUltra technology platform

• OmniUltra is a transgenic chicken platform engineered to produce ultra-long CDRH3 antibodies with human sequences, enabling access to unique binding pockets and creation of novel picobodies and peptides for diverse therapeutic uses.

• The platform leverages evolutionary distance to generate robust immune responses and antibody diversity, supporting applications in bispecifics, multispecifics, CAR-T, radiopharma, and peptide therapeutics.

• OmniUltra enables discovery of mini-proteins, structured peptides, and autonomous binding fragments, expanding beyond traditional antibody discovery.

• Early data show strong immune responses to a variety of therapeutically relevant targets, including those 100% conserved in mammals, with broad applicability and industry engagement underway.

• Presentations at scientific conferences highlight the platform's innovation and capabilities.

Scientific, market, and business impact

• OmniUltra's in vivo optimization process, termed Biological Intelligence, increases efficiency and success rates in therapeutic discovery by producing naturally optimized candidates.

• The platform addresses a growing market for peptide therapeutics, with over 130 companies identified as potential partners and the market projected to exceed $1 trillion by 2034.

• The technology enables new deal structures, milestone payments, royalties, and stackable revenue streams as programs reach the market.

• OmniUltra is highly scalable, can be leveraged within existing infrastructure, and requires no significant incremental investment.

• Risks include market acceptance, partner development outcomes, regulatory changes, and competitive pressures.

Partner and market engagement

• Three early adopter partner programs are underway, with strong interest from existing and new partners and increasing business development activity post-launch.

• The platform is applicable to a wide range of modalities, including bispecifics, radiopharma, and CAR-T engagers.

• The company expects adoption to grow, with updates on new partners and programs to be provided over time.

• Structured partner agreements include upfront fees, service revenue, milestones, royalties, and revenue sharing.

• No change in overall business strategy; focus remains on creating technologies that meet industry needs and leveraging efficient operations.